Press Release

Monkeypox Therapeutics Market to Grow with a CAGR of 8.82% through 2029

Surge in research and development activities is expected to drive the Global Monkeypox Therapeutics Market growth in the forecast period, 2025-2029.

 

According to TechSci Research report, “Monkeypox Therapeutics Market - Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2029F”, the Global Monkeypox Therapeutics Market stood at USD 85.26 Million in 2023 and is anticipated to grow with a CAGR of 8.82% through 2029. Initiatives taken by government based on monkeypox therapeutics has led to favorable market conditions for the Global Monkeypox Therapeutics Market. Several factors contribute to the growth of various monkeypox therapeutics products.

To support the development of Monkeypox therapeutics, governments have significantly increased funding for research and development (R&D). This funding supports both public and private sector initiatives aimed at advancing the discovery and manufacturing of novel antiviral drugs and vaccines. For instance, the U.S. National Institutes of Health (NIH) and the European Commission have allocated grants to research institutions and pharmaceutical companies working on Monkeypox-related projects. This financial support accelerates the development pipeline and fosters innovation in therapeutic solutions.

In anticipation of potential outbreaks, governments have implemented stockpiling strategies for smallpox vaccines and antiviral medications. These stockpiles are strategically maintained to ensure that sufficient quantities of therapeutics are available for rapid deployment in the event of an outbreak. For example, the U.S. Centers for Disease Control and Prevention (CDC) has established a stockpile of smallpox vaccines, which can be used to address Monkeypox cases. Additionally, governments are working to enhance distribution networks to ensure that vaccines and treatments reach remote and underserved areas efficiently.

The escalating monkeypox cases have catalyzed an unprecedented surge in R&D activities within the pharmaceutical and biotech industries. Researchers and companies are actively engaged in developing new therapeutics, including antivirals, vaccines, and monoclonal antibodies. The drive to discover and bring effective treatments to market quickly is a response to the urgent need for effective solutions to combat monkeypox.

This acceleration in innovation is marked by increased funding and resources allocated to R&D efforts. Pharmaceutical companies and research institutions are dedicating substantial investments to explore novel compounds and treatment modalities. The result is a growing pipeline of promising therapeutics, each with the potential to transform the management of monkeypox and address gaps in current treatment options.


Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Monkeypox Therapeutics Market

 

The Global Monkeypox Therapeutics Market is segmented into treatment, end user, regional distribution, and company.

Based on Treatment, Antivirals have emerged as the dominating segment in the Global Monkeypox Therapeutics Market in 2023. Antiviral medications have demonstrated significant effectiveness in treating viral infections, including those caused by orthopoxviruses, the family to which Monkeypox belongs. Drugs like Tecovirimat (TPOXX) and Cidofovir, originally developed for smallpox, have been shown to be effective against Monkeypox due to their ability to inhibit viral replication. The success of these antivirals in clinical settings and their historical use in controlling similar viral outbreaks bolster their dominance in the Monkeypox Therapeutics Market. Their established efficacy provides a reliable treatment option, making them the preferred choice for managing Monkeypox infections.

Antivirals are particularly advantageous for treating Monkeypox because they target specific aspects of the virus's life cycle. For instance, Tecovirimat works by inhibiting the viral envelope protein, which is crucial for the virus's ability to spread. This targeted approach helps in reducing the viral load and alleviating symptoms more effectively than broad-spectrum treatments. The specificity of these antivirals to orthopoxviruses, including Monkeypox, enhances their effectiveness and reduces the risk of resistance development, contributing to their dominance in the market.

Based on Region, Asia Pacific have emerged as the fastest growing region in the Global Monkeypox Therapeutics Market in 2023. Countries in Asia Pacific are significantly expanding and upgrading their healthcare infrastructure to address emerging public health threats. Investments in healthcare facilities, diagnostic capabilities, and treatment availability have created a more robust environment for the deployment of monkeypox therapeutics.

There has been a surge in strategic partnerships and collaborations between local pharmaceutical companies and international organizations. These collaborations facilitate the transfer of technology, knowledge, and resources, enhancing the development and accessibility of monkeypox therapeutics in the region.

 

Major companies operating in Global Monkeypox Therapeutics Market are:

  • Chimerix Inc.
  • SIGA Technologies, Inc.
  • Emergent BioSolutions Inc.
  • Bavarian Nordic A/S
  • Hetero Drugs Limited
  • Mylan N.V.
  • Piramal Enterprises Limited
  • Olon S.p.A.
  • Teva Pharmaceutical Industries Limited
  • CIDIC Company Limited

 

Download Free Sample Report

Customers can also request for 10% free customization on this report

 

“Nanotechnology enhances diagnostic capabilities through the development of advanced nanosensors and nanoparticle-based assays. Nanoparticles, such as gold and quantum dots, are employed in diagnostic tests to improve sensitivity and specificity. In Monkeypox diagnostics, these nanoparticles can be engineered to bind selectively to viral antigens or genetic material, enabling rapid and accurate detection. This is crucial for timely diagnosis and effective outbreak management”, said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

Monkeypox Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment (Smallpox Vaccine, Antivirals, Vaccinia Immune Globulin (VIG)), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others), By Region and Competition, 2019-2029F”, has evaluated the future growth potential of Global Monkeypox Therapeutics Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Monkeypox Therapeutics Market.

 

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com